Cancer Family
Lung Neoplasm
CI-CAN-00000221Explore in graph →
Non-malignant2,724 active trials51 approved drugs619 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000221Explore in graph →
Clinical trials
11,600 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04706962 | TH1902 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 70 | TheratechnologiesINDUSTRY | 2 | Apr 15, 2025 | clinicaltrials |
| NCT06537804 | Project Lung Cancer Screening in Southern Denmark(PLUS) | active not recruiting | N/A | 1,332 | Odense University HospitalOTHER | 1 | Apr 15, 2025 | clinicaltrials |
| NCT06926803 |
| A Clinical Study of Furmonertinib in the Treatment of EGFR-Mutated NSCLC With Leptomeningeal Metastases |
| active not recruiting |
| — |
| 500 |
| Qiming WangOTHER_GOV |
| 1 |
| Apr 15, 2025 |
| clinicaltrials |
| NCT06900283 | Quality of Life as a Predictor of OS and PFS in Patients With Lung Cancer(FACT-L_Pred) | active not recruiting | — | 320 | Instituto Nacional de Cancerologia, ColumbiaOTHER_GOV | 1 | Apr 3, 2025 | clinicaltrials |
| NCT04802876 | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors(ACROPOLI) | active not recruiting | Phase 2 | 184 | SOLTI Breast Cancer Research GroupOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT04585035 | Study to Evaluate D-1553 in Subjects With Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 180 | InventisBio Co., LtdINDUSTRY | 4 | Mar 18, 2025 | clinicaltrials |
| NCT04263467 | High Intensity Aerobic Exercise Training and Immune Cell Mobilization in Patients With Lung Cancer (HI AIM)(HIAIM) | active not recruiting | N/A | 54 | Herlev HospitalOTHER | 1 | Mar 17, 2025 | clinicaltrials |
| NCT05844150 | A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC | active not recruiting | Phase 2 | 50 | Biotheus Inc.INDUSTRY | 1 | Mar 12, 2025 | clinicaltrials |
| NCT06863818 | Overcoming Resistance to EGFR Neutralization by Combination of Monoclonal Antibodies and Novel Cancer Drugs | active not recruiting | — | 30 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT06748495 | Real-world First-line Serplulimab-based Immunochemotherapy for Extensive-stage Small Cell Lung Cancer | active not recruiting | — | 600 | Hunan Cancer HospitalOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT04165330 | Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 56 | Sarcoma Oncology Research Center, LLCOTHER | 1 | Feb 24, 2025 | clinicaltrials |
| NCT06835231 | Broncho-Vascular Lung Sparing Reconstructions and Pneumonectomies in Patients With Non Small Cell Lung Cancer | active not recruiting | — | 140 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT06827145 | Combination of Vebreltinib and Osimertinib in Patients with EGFR 21 L858R Mutation Advanced NSCLC | active not recruiting | Phase 2 | 30 | National Cancer Center, ChinaOTHER | 1 | Feb 14, 2025 | clinicaltrials |
| NCT06808113 | Circulating and Molecular Markers Involved in the Processes of Cachexia, Anorexia and Sarcopenia in Patients With NSCLC(SARCLUNG) | active not recruiting | — | 40 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT04878445 | Tissue Engineering Approaches to Treat COPD | active not recruiting | — | 30 | University Hospitals of North Midlands NHS TrustOTHER | 1 | Feb 4, 2025 | clinicaltrials |
| NCT03212404 | Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | active not recruiting | Phase 1 | 272 | Checkpoint Therapeutics, Inc.INDUSTRY | 9 | Feb 3, 2025 | clinicaltrials |
| NCT03944772 | Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)(ORCHARD) | active not recruiting | Phase 2 | 247 | AstraZenecaINDUSTRY | 9 | Jan 30, 2025 | clinicaltrials |
| NCT04597671 | Durvalumab and Low-dose PCI vs Durvalumab and Observation in Radically Treated Patients With Stage III NSCLC (NVALT28)(NVALT28) | active not recruiting | Phase 3 | 170 | Association NVALT StudiesOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT06794957 | A Study of AL8326 in Non-Small Cell Lung Cancer | active not recruiting | Phase 1 | 158 | Advenchen Laboratories, LLCINDUSTRY | 1 | Jan 27, 2025 | clinicaltrials |
| NCT06480734 | Pneumonitis in Older Lung Cancer Patients After Radiotherapy(POLCAR) | active not recruiting | N/A | 62 | University Hospital Schleswig-HolsteinOTHER | 2 | Jan 16, 2025 | clinicaltrials |
| NCT03546361 | CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer | active not recruiting | Phase 1 | 24 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jan 14, 2025 | clinicaltrials |
| NCT04440735 | A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 125 | Kahr MedicalINDUSTRY | 1 | Jan 9, 2025 | clinicaltrials |
| NCT05688280 | Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS(INJECTABL-1) | active not recruiting | Phase 1 / Phase 2 | 42 | Immunophotonics, Inc.INDUSTRY | 5 | Jan 8, 2025 | clinicaltrials |
| NCT05712902 | Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6) | active not recruiting | Phase 2 | 104 | Dizal PharmaceuticalsINDUSTRY | 1 | Dec 30, 2024 | clinicaltrials |
| NCT06751108 | Impact of Concomitant Use of Steroids and Immune-Checkpoint Inhibitors on Survival Outcomes in NSCLC Patients | active not recruiting | — | 2,000 | Seoul National UniversityOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT05879068 | A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC | active not recruiting | Phase 2 | 99 | Biotheus Inc.INDUSTRY | 1 | Dec 18, 2024 | clinicaltrials |
| NCT02515760 | Tumor-specific T Cells in Lung Cancer | active not recruiting | N/A | 120 | University Hospital HeidelbergOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT04794010 | A Study in Participants With First-Line Nivolumab Plus Ipilimumb Therapy Combined With Two Cycles of Chemotherapy for Metastatic Non-Small Cell Lung Cancer(FINN) | active not recruiting | — | 825 | Bristol-Myers SquibbINDUSTRY | 1 | Dec 12, 2024 | clinicaltrials |
| NCT06247280 | Korean Registry of Non-Small Cell Lung Cancer Patients with EGFR Mutation | active not recruiting | — | 2,001 | Yuhan CorporationINDUSTRY | 1 | Dec 6, 2024 | clinicaltrials |
| NCT03934866 | The SUMMIT Study: A Cancer Screening Study(SUMMIT) | active not recruiting | — | 13,035 | University College, LondonOTHER | 1 | Dec 5, 2024 | clinicaltrials |
| NCT04956692 | Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86) | active not recruiting | Phase 3 | 531 | Merck Sharp & Dohme LLCINDUSTRY | 16 | Dec 3, 2024 | clinicaltrials |
| NCT04923906 | Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mutations | active not recruiting | Phase 3 | 624 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 25, 2024 | clinicaltrials |
| NCT05128487 | A Study of NDI 1150-101 in Patients With Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 106 | Nimbus Saturn, Inc.INDUSTRY | 1 | Nov 25, 2024 | clinicaltrials |
| NCT04699721 | Clinical Study of Neoadjuvant Chemotherapy and Immunotherapy Combined With Probiotics in Patients With Resectable NSCLC | active not recruiting | Phase 2 | 60 | Xiangya Hospital of Central South UniversityOTHER | 1 | Nov 22, 2024 | clinicaltrials |
| NCT06700421 | Phase II Clinical Study of Adebrelimab Combined with Apatinib in the Treatment of Locally Advanced Non-small Cell Lung Cancer Patients with Radiation Pneumonitis | active not recruiting | Phase 2 | 32 | Wei ZhouOTHER | 1 | Nov 22, 2024 | clinicaltrials |
| NCT01553942 | Afatinib With CT and RT for EGFR-Mutant NSCLC | active not recruiting | Phase 2 | 19 | Massachusetts General HospitalOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT05199272 | A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies | active not recruiting | Phase 1 / Phase 2 | 141 | 23andMe, Inc.INDUSTRY | 2 | Nov 15, 2024 | clinicaltrials |
| NCT04687241 | Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations | active not recruiting | Phase 3 | 192 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 7, 2024 | clinicaltrials |
| NCT04127110 | Activity of Lorlatinib Based on ALK Resistance Mutations Detected on Blood in ALK Positive NSCLC Patients(ALKALINE) | active not recruiting | Phase 2 | 68 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 7 | Nov 5, 2024 | clinicaltrials |
| NCT05566041 | A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer(REPLATINUM) | active not recruiting | Phase 3 | 292 | EpicentRx, Inc.INDUSTRY | 1 | Oct 31, 2024 | clinicaltrials |
| NCT02611570 | LDCT Screening in Non-smokers in Taiwan | active not recruiting | — | 12,000 | Academia Sinica, TaiwanOTHER | 1 | Oct 30, 2024 | clinicaltrials |
| NCT05400070 | Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLC | active not recruiting | Phase 2 | 45 | Tang-Du HospitalOTHER | 1 | Oct 18, 2024 | clinicaltrials |
| NCT04806399 | Improving Utilization of Lung Cancer Screening in Underserved PA Populations | active not recruiting | N/A | 2,500 | American College of RadiologyOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT05620134 | Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer | active not recruiting | Phase 1 / Phase 2 | 263 | Salubris Biotherapeutics IncINDUSTRY | 2 | Oct 15, 2024 | clinicaltrials |
| NCT05215574 | Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 130 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | Oct 10, 2024 | clinicaltrials |
| NCT06616909 | Advance Care Planning Impact on the Consistency of Older Adults With Lung Cancer and Their Potential Surrogates Regarding Life-Sustaining Treatment Preferences | active not recruiting | N/A | 120 | National Taiwan University HospitalOTHER | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06569420 | Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC | active not recruiting | Phase 3 | 275 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.INDUSTRY | 1 | Aug 26, 2024 | clinicaltrials |
| NCT04685070 | Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung Cancer | active not recruiting | Phase 2 | 56 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Aug 14, 2024 | clinicaltrials |
| NCT05015010 | Alectinib in Neo-adjuvant Treatment of Stage III NSCLC(ALNEO) | active not recruiting | Phase 2 | 33 | Gruppo Oncologico Italiano di Ricerca ClinicaOTHER | 1 | Aug 9, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Apr 15, 2025source: clinicaltrials